Novel use of natural amentoflavone in curing viral diseases

A technology of biflavonoids and viral diseases, which is applied in the field of medicine and can solve problems such as no related reports.

Inactive Publication Date: 2010-06-23
SHENYANG PHARMA UNIVERSITY
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report on the effect of biflavonoids of Suicha chinensis on the treatment of viral diseases such as hepatitis B virus and influenza virus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel use of natural amentoflavone in curing viral diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1: Inhibitory effect of amentoflavone on hepatitis B virus.

[0013] Materials and Methods

[0014] 1. In vitro cell model: HepG2 cells transfected with hepatitis B virus (HBV), namely HepG2 2.215 cells.

[0015] 2. MTT method was used to detect the toxicity of samples to cells.

[0016] 3. Enzyme-linked immunoassay (EIA) was used to detect the inhibitory effect of samples on HBsAg and HBeAg.

[0017] Experimental procedure

[0018] 1. Cytotoxicity detection of drugs

[0019] After HepG2 2.2.15 cells were cultured in a 96-well cell culture plate for 48 hours, different concentrations of drug-containing culture medium were added, and the culture was continued for 9 days (the medium was changed once every 3 days). 2.2.15 Toxic concentration of cells.

[0020] 2. Detection of inhibitory effect of drugs on HBV virus antigen

[0021] After HepG2 2.2.15 cells were cultured in a 96-well cell culture plate for 48 hours, a series of drug-containing culture solution...

Embodiment 2

[0024] Example 2: Materials and methods for the detection of herpes virus inhibitory activity of amentoflavone in vitro

[0025] 1. In vitro host cells: Vero cells.

[0026] 2. Virus strain: herpes simplex virus type I (HSV-I).

[0027] 3. CPE method to detect the toxicity of drugs to cells.

[0028] 4. CPE method (cytopathic) to detect the inhibitory effect of drugs on herpes virus.

[0029] Antiviral test process

[0030] 1. Cytotoxicity detection of drugs

[0031] After Vero cells were cultured in a 96-well cell culture plate to form a monolayer, drug solutions of different concentrations were added and cultured for 3 days, and the toxicity of drugs to Vero cells was detected by CPE method.

[0032] 2. Drug anti-herpes virus detection

[0033] After Vero cells were cultured in a 96-well cell culture plate to form a monolayer, the cells were infected with 10TCID50 of HSV-I, and then a series of drug-containing culture solutions at non-toxic concentrations were added, an...

Embodiment 3

[0036] Example 3: Materials and methods for the detection of anti-influenza virus activity of amentoflavone in vitro

[0037] 1. In vitro host cells: MDCK cells.

[0038] 2. Virus strain: Influenza virus type A (H1N1) (A3 / Jingke / 30 / 95).

[0039] 3. CPE method to detect the toxicity of drugs to cells.

[0040] 4. CPE method (cytopathic) to detect the inhibitory effect of drugs on influenza virus.

[0041] Experimental procedure

[0042] 1. Cytotoxicity detection of drugs

[0043] After MDCK cells were cultured in a 96-well cell culture plate to form a monolayer, different concentrations of drug solutions were added, and the culture was continued for 3 days. The toxicity of drugs to MDCK cells was detected by CPE method.

[0044] 2. Drug anti-influenza virus detection

[0045] After the MDCK cells were cultured in a 96-well cell culture plate to form a monolayer, the cells were infected with 100 TCID50 of influenza virus, and then a series of drug-containing culture medium at...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel use of natural amentoflavone compound in curing viral diseases. The natural amentoflavone compound is extracted from plants, Chinese medicinal materials or prepared herbal medicine in small pieces ready for decoction, which contain the components of amentoflavone. Through conventional methods, the compound is used as medicinal ingredients to prepare pharmaceutical preparations for curing viral diseases, and can be used separately or be combined with acceptable excipient in the pharmaceutical process to prepare oral preparations of troches, capsules, granules, sustained-release preparations, dropping pills and the like, to prepare gels, suppository and the like to be used in cavities such as the vagina, the anus, the nasal cavity and the like, and to prepareinjections for use in muscles or veins. The content of amentoflavone is above 90 percent. The invention discloses the effective ingredient of the Chinese herbal Selaginella in the curing viral diseases, provides a scientific basis for clinical application of Selaginella and enables amentoflavone to be used as a natural antiviral agent, and the antiviral agent causes no addiction and is small in dosage.

Description

Technical field: [0001] The invention relates to the technical field of medicine, and relates to a new application of amentoflavone in the pharmaceutical field, in particular to a new application of amentoflavone in treating viral diseases. Background technique: [0002] Various hepatitis viruses such as hepatitis B virus and viral infectious diseases caused by various respiratory viruses are a group of common diseases. The incidence rate is gradually increasing in the world, and new pathogenic viruses are constantly emerging. For example, atypical pneumonia (SARS), which was popular in some provinces and cities in my country in early 2003, is a serious viral infectious disease caused by a mutant virus of coronavirus. Also, the H5N1 virus that appeared the year before last and the H1N1 virus infection that is currently appearing are all viral infectious diseases. [0003] The hazards of viral infectious diseases are not only the various infections caused by them, but more i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P31/12A61P31/20A61P31/22A61P31/16
Inventor 张国刚田宏
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products